During the past decade, Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg" are "Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer" (1 trials), "Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer" (1 trials) and "Non-Small Cell Lung Cancer (NSCLC)" (1 trials). Many other conditions were trialed in "Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg" in a lesser frequency.

Most popular intervention types in "Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Fulvestrant" (1 trials), "Fulvestrant or an Aromatase Inhibitor (Physician Choice)" (1 trials), "Giredestrant" (1 trials) and "LHRH Agonist" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg" are 2 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".